COMP <GO>
HROW vs ABBV // 10Y YIELD & FRED MACRO BETA
Harrow Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HROW 4
— ABBV 7
■ METRIC PARITY
LAST: $29.99 (+2.04%) • MKT CAP: $1.12B
macro-sensitivity
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HROW | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.10% | 70.20% | +4.90 | HROW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.90% | 29.00% | +13.90 | HROW | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.6x | 33.3x | +0.30 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.82% | 3.47% | +0.35 | HROW | /fcf-yield <GO> |
| Operating Margin | 11.20% | 24.60% | -13.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -1.90% | 6.90% | -8.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 36.40% | 8.60% | +27.80 | HROW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.67 | 5.33 | -2.66 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 65.1 | -15.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $513.86B | -$512.74B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HROW REV | ABBV REV | HROW GROSS % | ABBV GROSS % | HROW FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $272.3M | $61.16B | 75.1% | 70.2% | $43.0M | $17.82B |
| FY 2024 | $199.6M | $56.33B | 75.3% | 70.0% | -$23.8M | $17.83B |
| FY 2023 | $130.2M | $54.32B | — | — | $3.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
ABBV // BETA 1.15